Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2/3
Terminated
NCT04815967
| Condition | Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury |
|---|
| Phase | Phase 2/3 |
|---|
| Sponsor | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC |
|---|
| Status | Terminated |
|---|
| Enrollment | 32 participants |
|---|
| Interventions | Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo |
|---|
| Start date | Nov 2, 2021 |
|---|
| Completion date | Apr 23, 2023 |
|---|
| Results posted | May 27, 2026 |
|---|
Summary
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension safety trial.
The Change From Baseline in Modified Ashworth Scale (MAS) Score for Tone of the Primary Target Muscle Group (PTMG) Selected for Treatment at Week 4 Post-injection.
Baseline and Week 4 · units on a scale
| Phase 2 (DBP); High Dose MYOBLOC (15,000 Units) | 2.90 ± 0.568 units on a scale |
|---|
| Phase 2 (DBP); Low Dose MYOBLOC (10,000 Units) | 2.82 ± 0.405 units on a scale |
|---|
| Phase 2 (DBP); Placebo | 2.73 ± 0.467 units on a scale |
|---|
| Phase 2 (DBP); High Dose MYOBLOC (15,000 Units) | 2.05 ± 0.762 units on a scale |
|---|
| Phase 2 (DBP); Low Dose MYOBLOC (10,000 Units) | 1.82 ± 0.681 units on a scale |
|---|
| Phase 2 (DBP); Placebo | 2.65 ± 0.580 units on a scale |
|---|
The Clinical Global Impression of Change (CGI-C) Score in Functional Ability at Week 4 Post-injection.
Week 4 · score on a scale
| Phase 2 (DBP); High Dose MYOBLOC (15,000 Units) | 2.4 ± 0.70 score on a scale |
|---|
| Phase 2 (DBP); Low Dose MYOBLOC (10,000 Units) | 2.6 ± 0.67 score on a scale |
|---|
| Phase 2 (DBP); Placebo | 3.3 ± 0.48 score on a scale |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.